Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TP-06 · 1 trial · 1 indication
A participant will be considered to have achieved complete resolution of CFS when there is no residual fluorescein staining at the time of assessment and at the follow-up assessment.
| Arm | Type | Description |
|---|---|---|
| TP-06 Ophthalmic Solution | ACTIVE_COMPARATOR | - |
| Vehicle of TP-06 Ophthalmic Solution | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| TP-06 | DRUG | TP-06 ophthalmic solution |
| Vehicle of TP-06 | DRUG | Vehicle of TP-06 ophthalmic solution |
Inclusion Criteria: * Able and willing to provide written informed consent * Presence of a non-infected persistent corneal epithelial defect (PCED) in one eye that has failed to heal after at least 10 days of appropriate standard-of-care treatment * Stable lesion size between Screening and Baseline...